CommercialPrior AuthMedium impact
Imetelstat (Rytelo™
BCBS Tennessee·TN · Hematology, Oncology, Internal Medicine·Medical Policy
Effective date
Sep 30, 2026
We identified it
Jul 17, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for Imetelstat (Rytelo™) effective 9/30/2026, covering treatment of lower-risk myelodysplastic syndromes with transfusion-dependent anemia. The policy requires prior authorization for initial 24-week treatment and 6-month continuation therapy, with specific clinical criteria including failed ESA/luspatercept response and transfusion burden thresholds. Billing teams must prepare authorization workflows and clinical documentation requirements before the effective date.
Action Required
By September 30, 2026: Billing and authorization teams must implement prior authorization workflow for Imetelstat (Rytelo™) claims. Providers must document: (1) MDS diagnosis with IPSS-R risk category (very low, low, or intermediate), (2) transfusion dependency history (≥4 RBC units per 8 weeks), (3) prior ESA or luspatercept failure/ineligibility with sEPO levels if applicable, and (4) for continuation therapy, evidence of transfusion burden reduction and absence of unacceptable toxicity. Update billing system to require prior authorization before claim submission for this drug. Update prior authorization request forms and templates to capture IPSS-R scores and transfusion burden documentation. Train authorization staff on clinical approval criteria. Create internal alerts for 6-month continuation reviews. Failure to obtain prior authorization will result in claim denials.